Med Worm: Keyword Buprenorphine

This paper traces the early 21st century success of the agonist–antagonist buprenorphine and the combination drug buprenorphine with naloxone within the broader quest to develop addiction therapeutics that began in the 1920s as the search for a nonaddictive analgesic. Drawing on archival research, document analysis, and interviews with contemporary actors, this paper situates the social organization of laboratory‐based and clinical research within the domestic and international confluence of several issues, including research ethics, drug regulation, public attitudes, tensions around definitions of drug addiction, and the evolving roles of the pharmaceutical industry. The fervor that drove the champions of buprenorphine must be understood in relation to (1) the material work of researc...

Updated Date: Jan 18, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

CONCLUSIONS  Office-based bup/nx for clinically stable patients may be a cost-effective alternative to no treatment at a threshold of $100,000/QALY depending on assumptions about quality-of-life weights. Additional research about quality-of-life benefits and broader health system and societal cost savings of bup/nx therapy is needed. Content Type Journal ArticleCategory Original ResearchPages 1-8DOI 10.1007/s11606-011-1962-8Authors Bruce R. Schackman, Department of Public Health, Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, USAJared A. Leff, Department of Public Health, Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, USADaniel Polsky, Division of Internal Medicine, University of Pennsylvania School of Medicine, Phi...

Alexander Gettler Taking inspiration from New York Times columnist David Brooks and his annual Sidney Awards for the best magazine essays of the preceding year, TPR is proud to present its Alexander Awards for the best toxicology writing on the web in 2011. The awards are named after Alexander Gettler, who was New York City’s chief toxicologist in the early twentieth century. To be eligible for an Alexander, the article or post must be freely and fully accessible, and not imprisoned behind some firewall, purchase plan, or subscription fee. Unfortunately, this eliminates from consideration nearly every paper that has appeared in a major medical journal this year. However, some fascinating journal articles are available — in toto – on the web. In Substance Abuse, Katshu e...

Conclusion Buprenorphine is a safe and effective agent for detoxification from opioids. It can be used as a first-line agent in maintenance programs, owing to its lower abuse potential relative to other opioids. Its effectiveness in primary care settings makes it a useful therapeutic tool for family physicians. PMID: 22267618 [PubMed - in process] (Source: Canadian Family Physician Medecin de Famille Canadien)

Conclusions: The increases in diversion and abuse measures indicate the need to take active attempts to curb diversion and abuse as well as continuous monitoring and surveillance of all buprenorphine products. However, these increases parallel the increased number of tablets sold. Finding a balance of risk/benefit (i.e. diversion and abuse versus expanded treatment) remains a challenge. (Source: Drug and Alcohol Dependence)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Conclusions  Prescription opioid–dependent patients are most likely to reduce opioid use during buprenorphine-naloxone treatment; if tapered off buprenorphine-naloxone, even after 12 weeks of treatment, the likelihood of an unsuccessful outcome is high, even in patients receiving counseling in addition to SMM. Trial Registration  clinicaltrials.gov Identifier: NCT00316277 (Source: Archives of General Psychiatry)

WARREN, N.J., Nov. 30, 2011 (GLOBE NEWSWIRE) -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm(r) drug delivery technology and a drug delivery company specializing in film pharmaceutical products, announced that the U.S. Food and Drug Administration (FDA) has listed MonoSol Rx's U.S. Patent No. 8,017,150 in the Orange Book for the Suboxone(r) (buprenorphine HCl and naloxone HCl dihydrate) sublingual film products. (Source: Medical News (via PRIMEZONE))

Buprenorphine is an effective treatment for opiate dependence. Prisoners with histories of opiate dependence who are inducted on buprenorphine prior to release are at decreased risk of post-release relapse and overdose, yet many clinicians are unaware of the risks related to buprenorphine induction for non-opiate tolerant patients, especially those on other psychotropic medications. The authors report a case of probable non-lethal overdose during dose induction of a non-tolerant prisoner and discuss appropriate dosing under similar circumstances. (Source: Addictive Disorders and Their Treatment)

I recently blogged about Buprenorphine, a medication that can help get heroin and other opiate addicts through detox and heroin withdrawal. Today, I'm writing about another medication, Suboxone. Suboxone contains Buprenorphine, but it also contains another ingredient that helps with the process of overcoming addiction. And research shows that it can help with relapse prevention over the longer term, as well as withdrawal in the short term. (Source: About.com Addictions)

Buprenorphine-naloxone may decrease dependence in patients addicted to prescription opioids, but only after extended and/or ongoing treatment. Medscape Medical News (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

NEW YORK (Reuters Health) - Buprenorphine-naloxone (Suboxone, Reckitt-Benckiser) helps curb prescription opioid dependence, but additional counseling does little to boost success rates, according to results of a randomized controlled trial published online November 7 in Archives of General Psychiatry. (Source: Modern Medicine)

People addicted to prescription painkillers reduce their opioid abuse when given sustained treatment with the medication buprenorphine plus naloxone (Suboxone), according to research published in Archives of General Psychiatry and conducted by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. The study, which was the first randomized large scale clinical trial using a medication for the treatment of prescription opioid abuse, also showed that the addition of intensive opioid dependence counseling provided no added benefit... (Source: Health News from Medical News Today)

Individuals addicted to prescription painkillers are more likely to succeed in treatment with the aid of the medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard Medical School researchers in the online edition of the Archives of General Psychiatry. "Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence," is the first large-scale study to address treatment of prescription opioid addiction... (Source: Health News from Medical News Today)

Source: National Institute on Drug Abuse - Related MedlinePlus Pages: Pain Relievers, Prescription Drug Abuse (Source: MedlinePlus Health News)

(NIH/National Institute on Drug Abuse) People addicted to prescription painkillers reduce their opioid abuse when given sustained treatment with the medication buprenorphine plus naloxone, according to research published in yesterday's Archives of General Psychiatry and conducted by NIDA, part of the NIH. (Source: EurekAlert! - Social and Behavioral Science)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Source: Arch Gen Psychiatry Area: News According to research published early online in the Archives of General Psychiatry, patients who are dependent on prescription opioids are most likely to reduce their use during treatment with buprenorphine-naloxone.  This effect is short lived however and reduces after treatment is tapered; the likelihood of a successful outcome is therefore low, even if counselling is also given.    The authors note that the abuse of prescription opioids is a growing public health concern; the majority of research on the treatment of this has however focused on heroin-dependent patients receiving methadone in specialised treatment programmes.  Evidence has suggested that patients dependent on prescription opioids have more favourable prognos...

We read with interest the recent article by Heather Martin entitled “The Possible Consequences of Combining Lorazepam and Buprenorphine/Naloxone: A Case Review.” It is an interesting case study and we would like to express our thoughts on the drug interactions among benzodiazepine and buprenorphine/naloxone based on the literature review. (Source: Journal of Emergency Nursing: JEN)

Conclusions  Prescription opioid–dependent patients are most likely to reduce opioid use during buprenorphine-naloxone treatment; if tapered off buprenorphine-naloxone, even after 12 weeks of treatment, the likelihood of an unsuccessful outcome is high, even in patients receiving counseling in addition to SMM. Trial Registration  clinicaltrials.gov Identifier: NCT00316277 (Source: Archives of General Psychiatry)

(McLean Hospital) Individuals addicted to prescription painkillers are more likely to succeed in treatment with the aid of the medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard Medical School researchers in today's online edition of the Archives of General Psychiatry. (Source: EurekAlert! - Social and Behavioral Science)